Hasnain Faheem — SEC Form 4 filings
SEC reporting owner CIK 1352620. 13 Form 4 filings on record with FilingPulse; latest filed 2026-08-26.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-01-23 to 2026-08-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 372,000 shares, $250,282 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 55,854 shares, $317,993 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 37.
- Largest priced transaction: purchase of 372,000 shares @ $0.67 ($250,282) in Gossamer Bio, Inc., filed 2024-06-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Kura Oncology, Inc. (KURA) | Director | 5 | — | 2 legs · 32,682 sh · $291,220 | 5 |
| Gossamer Bio, Inc. (GOSS) | President & CEO, Director | 7 | 1 leg · 372,000 sh · $250,282 | 1 leg · 23,172 sh · $26,773 | 26 |
| Mirati Therapeutics, Inc. (MRTX) | Director | 1 | — | — | 6 |
Form 4 filings — Hasnain Faheem
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-26 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 166 (derivative) @ $1,000.00 · Grant/award (A): 5,800,051 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Gossamer Bio, Inc. (GOSS) | Disposition to issuer (D): 1,680,000 (derivative) · Disposition to issuer (D): 1,540,000 (derivative) · Disposition to issuer (D): 1,312,500 (derivative) · Disposition to issuer (D): 437,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · +14 more | EDGAR |
| 2026-01-05 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 280,000 @ $0 · Grant/award (A): 1,680,000 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 10,000 @ $3.12 · Sale (S): 10,000 @ $10.98 | EDGAR |
| 2025-10-02 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 437,500 @ $0 | EDGAR |
| 2025-06-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2025-03-24 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 22,682 @ $6.32 · Sale (S): 22,682 @ $8 | EDGAR |
| 2025-03-06 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 1,540,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 372,000 @ $0.67 | EDGAR |
| 2024-06-07 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Gossamer Bio, Inc. (GOSS) | Sale (S): 23,172 @ $1.16 | EDGAR |
| 2024-01-23 | 4 | Mirati Therapeutics, Inc. (MRTX) | Disposition to issuer (D): 8,717 · Disposition to issuer (D): 6,333 · Disposition to issuer (D): 9,702 · Disposition to issuer (D): 35,000 (derivative) · Disposition to issuer (D): 10,716 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1352620 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →